Table 1

Baseline Demographic, Clinical, Biochemical, Angiographic, and Procedural Characteristics by Treatment Group

CharacteristicStatin
(n = 252)
Control
(n = 252)
p Value
Age, yrs66.2 ± 12.466.1 ± 13.50.91
Age ≥70 yrs117 (46.4)113 (44.8)0.72
Male166 (65.9)165 (65.5)0.93
BMI, kg/m226.2 ± 3.726.6 ± 4.40.35
Clinical presentation
 NSTE-MI233 (92.4)232 (92.1)>0.90
 Unstable angina19 (7.5)20 (7.9)>0.90
Risk factors
 Hypertension143 (56.7)138 (54.8)0.65
 Diabetes mellitus50 (19.8)57 (22.6)0.45
 Active smoking89 (35.3)81 (32.1)0.45
 Total cholesterol >200 mg/dl116 (46)130 (51.6)0.21
 eCrCl, ml/min69.9 ± 24.469.3 ± 24.90.81
 eCrCl <30 ml/min7 (2.8)9 (3.6)0.61
 eCrCl <60 ml/min105 (41.7)105 (41.7)>0.90
 eGFR, ml/min/m282.5 ± 282.6 ± 220.96
 eGFR <60, ml/min/m239 (15.5)37 (14.7)0.80
Previous MI24 (9.5)15 (5.9)0.13
Previous PCI or CABG30 (11.9)18 (7.1)0.07
Baseline LVEF, %50 ± 950 ± 9>0.90
EF <30%15 (5.9)14 (5.6)0.85
EF <45%84 (33.3)85 (33.7)0.93
High-risk clinical features180 (71.4)169 (67.1)0.29
Laboratory variables at baseline
 Serum creatinine, mg/dl0.95 ± 0.270.96 ± 0.280.89
 Haemoglobin, mg/dl14.1 ± 1.614.1 ± 1.60.77
 cTn-I, ng/ml2.3 ± 5.12.5 ± 7.00.41
 CK-MB, ng/ml19.2 ± 35.223.1 ± 48.80.34
 LDL cholesterol, mg/dl135.2 ± 38.6135.8 ± 42.70.85
 HDL cholesterol, mg/dl40.2 ± 13.742.3 ± 13.30.08
 Triglycerides, mg/dl119.7 ± 62.8118 ± 730.78
 Glycemia, mg/dl131.7 ± 50.1137.3 ± 53.40.23
Time intervals, h
Symptom onset-to-randomization10 (6–20)11.5 (6–24)0.11
Randomization-to-angiography22.5 (14–43)23 (15–45.5)0.79
Randomization-to-angiography distribution time
 within 24 h135 (53.6)135 (53.6)0.85
 within 48 h205 (81.3)194 (76.9)0.27
 after 48 h47 (18.6)58 (23)0.27
Hospital stay (days)5 (4-7)5 (4-7)>0.90
Angiographic data and treatment:
Multivessel disease123 (48.8)120 (47.6)0.78
Contrast volume (ml)149.7 ± 86.8138.2 ± 77.80.14
Contrast volume >140 (ml)117 (46.4)101 (40.1)0.15
Additional angiography
 within 72 h after first procedure11 (4.4)12 (4.8)0.83
Management distribution0.70
 Medical treatment54 (21.4)60 (23.8)
 CABG27 (10.7)30 (11.9)
 PCI171 (67.9)162 (64.3)
PCI data
 Multivessel PCI58 (33.9)46 (28.3)0.21
 Contrast volume, ml183 ± 80172 ± 720.18
 Contrast volume >140 ml111 (64.9)97 (59.8)0.20
Contrast nephropathy risk score3 (1–6)2 (1–5)0.36
Score distribution:0.62
 <5187 (74.2)192 (76.6)
 6–1057 (22.6)49 (19.4)
 11–168 (3.2)9 (3.6)
 >160 (0.0)1 (0.4)
Medications at coronary angiography
Beta-blockers113 (44.8)103 (40.8)0.41
ACE inhibitors94 (37.3)103 (40.8)0.71
Angiotensin receptor blockers25 (9.9)28 (11.1)0.77
Nitrates73 (28.9)66 (26.1)0.54
Diuretics68 (26.9)71 (28.1)0.84
Calcium channel blockers28 (11.1)26 (10.3)0.88
GP IIb/IIIa inhibitors31 (12.3)37 (14.6)0.51
Medications at discharge
Beta-blockers140 (55.7)133 (52.7)0.59
ACE inhibitors130 (51.7)131 (51.9)>0.90
Angiotensin receptor blockers25 (9.9)25 (9.9)>0.90
Nitrates48 (19.1)55 (21.8)0.49
Diuretics73 (29.1)78 (30.9)0.62
Calcium channel blockers40 (15.9)38 (15.1)0.90

Values are ± SD, n (%), or median (interquartile range).

ACE = angiotensin-converting enzyme; BMI = body mass index; CABG = coronary artery bypass graft; CK = creatine kinase; cTnI = cardiac troponin I; eCrCl = estimated creatinine clearance; eGFR = estimated glomerular filtration rate; GP = glycoprotein; HDL = high density lipoprotein; LDL = low density lipoprotein; LVEF = left ventricular ejection fraction; MI = myocardial Infarction; NSTE-MI = without ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention.

  • Parametric unpaired Student t test (with †Satterthwaite's correction for degrees of freedom) or the analogous nonparametric ‡Wilcoxon Mann-Whitney test was applied to quantitative variables. Chi-square or Fisher’s exact test was used for categorical variables.